Zarate, Carlos A.

The role of adipokines in the rapid antidepressant effects of ketamine

Machado-Vieira, R., Gold, P. W., Luckenbaugh, D. A., Ballard, E. D., Richards, E. M., Henter, I. D., De Sousa, R. T., Niciu, M. J., Yuan, P., & Zarate, C. A. (2017) · Molecular Psychiatry

Treatment of Major DepressionTryptophan and brain disorders

Cited by 102

Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants

Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionPsychedelics and Drug Studies

Cited by 99

Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression

Park, M., Newman, L. E., Gold, P. W., Luckenbaugh, D. A., Yuan, P., Machado-Vieira, R., & Zarate, C. A. (2017) · Journal of Psychiatric Research

Treatment of Major DepressionTryptophan and brain disorders

Cited by 93

Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine’s Rapid Antidepressant Properties

Duncan, W. C., Slonena, E., Hejazi, N. S., Brutsche, N., Yu, K. C., Park, L., Ballard, E. D., & Zarate, C. A. (2017) · Biological Psychiatry

Treatment of Major DepressionCircadian rhythm and melatonin

Cited by 93

Novel glutamatergic agents for major depressive disorder and bipolar disorder

Machado-Vieira, R., Ibrahim, L., Henter, I. D., & Zarate, C. A. (2012) · Pharmacology Biochemistry and Behavior

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 92

Hydroxynorketamines: Pharmacology and Potential Therapeutic Applications

Highland, J. N., Zanos, P., Riggs, L. M., Georgiou, P., Clark, S. M., Morris, P. J., Moaddel, R., Thomas, C. J., Zarate, C. A., Pereira, E. F. R., et al. (2021) · Pharmacological Reviews

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 92

D-serine plasma concentration is a potential biomarker of (R,S)-ketamine antidepressant response in subjects with treatment-resistant depression

Moaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 86

Baseline delta sleep ratio predicts acute ketamine mood response in major depressive disorder

Duncan, W. C., Selter, J., Brutsche, N., Sarasso, S., & Zarate, C. A. (2013) · Journal of Affective Disorders

Treatment of Major DepressionSleep and Wakefulness Research

Cited by 86

Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression

Farmer, C. A., Gilbert, J. R., Moaddel, R., George, J., Adeojo, L., Lovett, J., Nugent, A. C., Kadriu, B., Yuan, P., Gould, T. D., et al. (2020) · Neuropsychopharmacology

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 85

Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites

Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 83

International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators

Price, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 82

Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant

Ballard, E. D., Luckenbaugh, D. A., Richards, E. M., Walls, T. L., Brutsché, N. E., Ameli, R., Niciu, M. J., Vande Voort, J. L., & Zarate, C. A. (2015) · Journal of Psychiatric Research

Treatment of Major DepressionSuicide and Self-Harm Studies

Cited by 80

A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression

Richards, E. M., Mathews, D. C., Luckenbaugh, D. A., Ionescu, D. F., Machado-Vieira, R., Niciu, M. J., Duncan, W. C., Nolan, N. M., Franco-Chaves, J. A., Hudzik, T., et al. (2016) · Psychopharmacology

Treatment of Major DepressionNeuropeptides and Animal Physiology

Cited by 76

Ketamine, Sleep, and Depression: Current Status and New Questions

Duncan, W. C., & Zarate, C. A. (2013) · Current Psychiatry Reports

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 76

Cerebrospinal Fluid Metabolome in Mood Disorders-Remission State has a Unique Metabolic Profile

Kaddurah-Daouk, R., Yuan, P., Boyle, S. H., Matson, W., Wang, Z., Zeng, Z. B., Zhu, H., Dougherty, G. G., Yao, J. K., Chen, G., et al. (2012) · Scientific Reports

Tryptophan and brain disordersTreatment of Major Depression

Cited by 76

Blood-based biomarkers of antidepressant response to ketamine and esketamine: A systematic review and meta-analysis

Medeiros, G. C., Gould, T. D., Prueitt, W. L., Nanavati, J., Grunebaum, M. F., Farber, N. B., Singh, B., Selvaraj, S., Machado-Vieira, R., Achtyes, E. D., et al. (2022) · Molecular Psychiatry

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 75

The influence of ketamine on drug discovery in depression

Kraus, C., Wasserman, D., Henter, I. D., Acevedo-Diaz, E., Kadriu, B., & Zarate, C. A. (2019) · Drug Discovery Today

Treatment of Major DepressionElectroconvulsive Therapy Studies

Cited by 75

A pilot study of plasma metabolomic patterns from patients treated with ketamine for bipolar depression: evidence for a response‐related difference in mitochondrial networks

Villaseñor, A., Ramamoorthy, A., Silva dos Santos, M., Lorenzo, M. P., Laje, G., Zarate, C., Barbas, C., & Wainer, I. W. (2014) · British Journal of Pharmacology

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 71

Ketamine normalizes brain activity during emotionally valenced attentional processing in depression

Reed, J. L., Nugent, A. C., Furey, M. L., Szczepanik, J. E., Evans, J. W., & Zarate, C. A. (2018) · NeuroImage: Clinical

Treatment of Major DepressionTranscranial Magnetic Stimulation Studies

Cited by 67

Antisuicidal response following ketamine infusion is associated with decreased nighttime wakefulness in major depressive disorder and bipolar disorder

Vande Voort, J. L., Ballard, E. D., Luckenbaugh, D. A., Bernert, R. A., Richards, E. M., Niciu, M. J., Park, L. T., Machado-Vieira, R., Duncan, W. C., & Zarate, C. A. (2017) · The Journal of Clinical Psychiatry

Treatment of Major DepressionSuicide and Self-Harm Studies

Cited by 65

Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action

Du, J., Machado-Vieira, R., Maeng, S., Martinowich, K., Manji, H. K., & Zarate, C. A. (2006) · Drug Discovery Today: Therapeutic Strategies

Treatment of Major DepressionNeuroscience and Neuropharmacology Research

Cited by 64

New methods for assessing rapid changes in suicide risk

Ballard, E. D., Gilbert, J. R., Wusinich, C., & Zarate, C. A. (2021) · Frontiers in Psychiatry

Suicide and Self-Harm StudiesMental Health Research Topics

Cited by 63

A Randomized Trial of the N-Methyl-d-Aspartate Receptor Glycine Site Antagonist Prodrug 4-Chlorokynurenine in Treatment-Resistant Depression

Park, L. T., Kadriu, B., Gould, T. D., Zanos, P., Greenstein, D., Evans, J. W., Yuan, P., Farmer, C. A., Oppenheimer, M., George, J. M., et al. (2020) · International Journal of Neuropsychopharmacology

Treatment of Major DepressionTryptophan and brain disorders

Cited by 63

Positive AMPA receptor modulation in the treatment of neuropsychiatric disorders: A long and winding road

Kadriu, B., Musazzi, L., Johnston, J. N., Kalynchuk, L. E., Caruncho, H. J., Popoli, M., & Zarate, C. A. (2021) · Drug Discovery Today

Neuroscience and Neuropharmacology ResearchTreatment of Major Depression

Cited by 62